rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    QNRX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Quoin Pharmaceuticals shareholders approve amendment to ownership limitations
      Nov 12Investing.comQNRX
      Quoin Pharmaceuticals’ Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton Syndrome
      Nov 6MorningstarQNRX
      12 Health Care Stocks Moving In Monday's After-Market Session
      Nov 2BenzingaQNRX
      Quoin Pharmaceuticals to Announce Corporate Update and Third Quarter 2026 Financial Results on Thursday, November 5, 2026
      Oct 29Yahoo FinanceQNRX
      Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy
      Oct 20Yahoo FinanceQNRX
      Canaccord initiates Quoin Pharmaceuticals stock at buy on rare skin disease drug potential
      Oct 19Investing.comQNRX
      Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome
      Oct 14Yahoo FinanceQNRX
      BTIG initiates Quoin Pharmaceuticals stock with buy rating
      Oct 12Investing.comQNRX
      Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy

      Peer-Reviewed Paper Introduces QRX003 and Its Mechanism of Action in Netherton SyndromeCase Report Details Professor Alan Irvine’s Clinical Experience Treating a Pediatric Patient Under Quoin’s Compassionate Use Program ASHBURN, Va., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that a manuscript titled “An Investigational Mechanism

      Oct 6Yahoo FinanceQNRX
      Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

      – First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy – Second Fast Track Designation Granted to QRX003, in Addition to Netherton Syndrome – Fast Track Designation Facilitates Development and Expedites Regulatory Review of Therapies Addressing Serious Conditions with Significant Unmet Medical Need – Follows July 2026 FDA Clearance of the First-Ever IND Submitted for Peeling Skin Syndrome – Phase 2/3 Study Expected to Initiate in 2H 2026, Enrolling up to 12 Pediatric and

      Sep 22Yahoo FinanceQNRX
      Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU

      This New Video Explores the Daily Realities of Raising a Child with Netherton Syndrome, and Its Impact on the Whole FamilyASHBURN, Va., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the release of the latest episode in its NETHERTON NOW video series. This episode is about Aminah and is told by her adoptive mother, Laura Wright-Sext

      Sep 10Yahoo FinanceQNRX
      CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome

      Second Rare Pediatric Disease (RPD) Designation for QRX003FDA Previously Granted RPD Designation for QRX003 in Netherton SyndromeIf a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin May Receive a Freely Tradable Priority Review Voucher (PRV)Quoin Expects to Initiate Phase 2 Study in 2H 2026; Study Plans to Enroll up to 12 Pediatric and Adult Peeling Skin Patients in the U.S. and EuropeThere are Currently No Approved Treatments for Peeling Skin Syndrome ASHBURN,

      Sep 8Yahoo FinanceQNRX
      Quoin in line for priority review voucher if rare paediatric drug approved

      Quoin has now received two rare paediatric disease designations for its lead asset QRX003.

      Sep 8Yahoo FinanceQNRX
      Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome

      Second Rare Pediatric Disease (RPD) Designation for QRX003FDA Previously Granted RPD Designation for QRX003 in Netherton SyndromeIf a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin May Receive a Freely Tradable Priority Review Voucher (PRV)Quoin Expects to Initiate Phase 2 Study in 2H 2026; Study Plans to Enroll up to 12 Pediatric and Adult Peeling Skin Patients in the U.S. and EuropeThere are Currently No Approved Treatments for Peeling Skin Syndrome ASHBURN,

      Sep 8Yahoo FinanceQNRX
      Tuesday’s insider buys and sells: Quoin Pharma executives lead purchases
      Sep 2Investing.comQNRX
      Quoin Pharmaceuticals CEO Michael Myers buys $99,991 ADSs
      Sep 2Investing.comQNRX
      Quoin Pharmaceuticals COO Denise Carter buys $99,991 in ADSs
      Sep 2Investing.comQNRX
      Quoin Pharmaceuticals director Culverwell buys $29,992 in ADSs
      Sep 2Investing.comQNRX
      Quoin Pharmaceuticals CFO Lawlor buys $49,990 in company stock
      Sep 2Investing.comQNRX
      12 Health Care Stocks Moving In Friday's Intraday Session
      Aug 28BenzingaAEMDQNRX
      Dow Gains 100 Points; Chicago PMI Falls In August
      Aug 28BenzingaQNRX
      Quoin Pharmaceuticals Stock Surges Friday: What's Happening?
      Aug 28BenzingaQNRX
      12 Health Care Stocks Moving In Friday's Pre-Market Session
      Aug 28BenzingaAEMDQNRX
      Quoin Pharmaceuticals raises $30.8M in private placement
      Aug 28Investing.comQNRX
      Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million

      ASHBURN, Va., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has entered into a securities purchase agreement with new and existing healthcare-focused institutional investors to raise up to approximately $50.0 million in gross proceeds, including initial upfront funding of approximately $30.8 million and up to an additional a

      Aug 28Yahoo FinanceQNRX
      Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome

      Interim Analysis of the First Six Patients to Complete 12 Weeks of Treatment Met Pre-Specified Alpha Adjusted Target for Primary Endpoint with Statistical Significance Four of Six (66.7%) Participants Achieved the Target 1-Grade or Greater Improvement in Investigator Global Assessment at Week 12 (p=0.0087) With Statistical Significance versus the Pre-Specified Alpha of 0.0215Key Secondary Endpoint of Global Impression of Change Also Achieved Statistical Significance at Week 12 (p=0.0070) Versus

      Aug 28Yahoo FinanceQNRX
      QNRX: Believe Conditional FDA Approval of Proposed Brand Name Reflects QRX003 Nearing Potential Commercialization

      By M. Marin NASDAQ: QNRX READ THE FULL QNRX RESEARCH REPORT Among broadest development pipelines focused on rare dermatologic diseases, with three core markets identified – U.S., EU, Japan – & partnership sales network for ROW Quoin Pharmaceuticals (NASDAQ: QNRX), a late clinical stage, specialty pharmaceutical company focused on developing treatments for rare and orphan diseases, provided a

      Aug 27Yahoo FinanceQNRX

      This is the newest page. Registered accounts read further back.